| Name | Title | Contact Details |
|---|
BiPar Sciences Incorporated is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.
We are bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to our lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). We bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers. We are bold in our mission and purpose and aim for nothing less than a transformative impact on people`s lives.
Quva is a national provider specializing in health-system pharmacy services, focusing on sterile injectable compounding and advanced data software platforms. The company operates FDA-registered 503B outsourcing facilities that manufacture ready-to-administer compounded sterile pharmaceuticals, serving thousands of hospitals across the United States. Quva adheres to stringent cGMP standards and utilizes automation and integrated technologies to ensure a reliable supply of high-quality medications. Quvas operations are divided into two main divisions. Quva Pharma delivers essential sterile compounded medications, addressing supply chain reliability and medication shortages. Quva BrightStream offers a data analytics platform that aggregates and analyzes healthcare data, providing actionable insights to optimize pharmacy operations. The company emphasizes patient safety, transparent customer service, and a commitment to innovation and quality, making it a trusted partner for health systems and hospital pharmacies.
Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.